{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:31:26Z","timestamp":1792452686604,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01939-7","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:39:29Z","timestamp":1755614369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma interleukin-22 concentration and disease activity in inflammatory bowel disease"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-1604","authenticated-orcid":false,"given":"Claudia","family":"Cabrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fern\u00e1ndez-Llaneza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Sopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Fehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emon","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Neisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Gehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"1939_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.12740\/PP\/62382","volume":"50","author":"J Nowakowski","year":"2016","unstructured":"Nowakowski, J., Chrobak, A. A. & Dudek, D. Psychiatric illnesses in inflammatory bowel diseases - psychiatric comorbidity and biological underpinnings. Psychiatr. Pol. 50, 1157\u20131166 (2016).","journal-title":"Psychiatr Pol."},{"key":"1939_CR2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/apt.12669","volume":"39","author":"AJ Panara","year":"2014","unstructured":"Panara, A. J. et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment. Pharmacol. Ther. 39, 802\u2013810 (2014).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1939_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","volume":"22","author":"A Mikocka-Walus","year":"2016","unstructured":"Mikocka-Walus, A., Knowles, S. R., Keefer, L. & Graff, L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm. Bowel Dis. 22, 752\u2013762 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"1939_CR4","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1007\/s10620-020-06647-y","volume":"66","author":"S van Gennep","year":"2021","unstructured":"van Gennep, S. et al. Impaired quality of working life in inflammatory bowel disease patients. Dig. Dis. Sci. 66, 2916\u20132924 (2021).","journal-title":"Dig. Dis. Sci."},{"key":"1939_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","volume":"18","author":"C Le Berre","year":"2020","unstructured":"Le Berre, C., Ananthakrishnan, A. N., Danese, S., Singh, S. & Peyrin-Biroulet, L. Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment. Clin. Gastroenterol. Hepatol. 18, 14\u201323 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1939_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13062-020-00280-5","volume":"15","author":"L Petagna","year":"2020","unstructured":"Petagna, L. et al. Pathophysiology of Crohn\u2019s disease inflammation and recurrence. Biol. Direct. 15, 23 (2020).","journal-title":"Biol. Direct"},{"key":"1939_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.12688\/f1000research.20805.1","volume":"9","author":"RJ Porter","year":"2020","unstructured":"Porter, R. J., Kalla, R. & Ho, G. T. Ulcerative colitis: recent advances in the Understanding of disease pathogenesis. F1000Research 9, 294 (2020).","journal-title":"F1000Research"},{"key":"1939_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/ibd.20475","volume":"14","author":"V Holtta","year":"2008","unstructured":"Holtta, V. et al. IL-23\/IL-17 immunity as a hallmark of Crohn\u2019s disease. Inflamm. Bowel Dis. 14, 1175\u20131184 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"1939_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1084\/jem.20101712","volume":"208","author":"A Geremia","year":"2011","unstructured":"Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127\u20131133 (2011).","journal-title":"J. Exp. Med."},{"key":"1939_CR10","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/eji.201242598","volume":"42","author":"AL Croxford","year":"2012","unstructured":"Croxford, A. L., Mair, F. & Becher, B. IL-23: one cytokine in control of autoimmunity. Eur. J. Immunol. 42, 2263\u20132273 (2012).","journal-title":"Eur. J. Immunol."},{"key":"1939_CR11","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan, B. G. et al. Induction therapy with the selective interleukin-23 inhibitor Risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389, 1699\u20131709 (2017).","journal-title":"Lancet"},{"key":"1939_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ibd.20315","volume":"14","author":"S Schmechel","year":"2008","unstructured":"Schmechel, S. et al. Linking genetic susceptibility to Crohn\u2019s disease with Th17 cell function: IL-22 serum levels are increased in Crohn\u2019s disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel Dis. 14, 204\u2013212 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"1939_CR13","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","volume":"13","author":"P Pavlidis","year":"2022","unstructured":"Pavlidis, P. et al. Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nat. Comm. 13, 5820 (2022).","journal-title":"Nat. Comm."},{"key":"1939_CR14","doi-asserted-by":"publisher","first-page":"e20192195","DOI":"10.1084\/jem.20192195","volume":"217","author":"M Keir","year":"2020","unstructured":"Keir, M., Yi, Y., Lu, T. & Ghilardi, N. The role of IL-22 in intestinal health and disease. J. Exp. Med. 217, e20192195 (2020).","journal-title":"J. Exp. Med."},{"key":"1939_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1053\/j.gastro.2005.06.071","volume":"129","author":"A Andoh","year":"2005","unstructured":"Andoh, A. et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129, 969\u2013984 (2005).","journal-title":"Gastroenterology"},{"key":"1939_CR16","doi-asserted-by":"publisher","first-page":"114273","DOI":"10.1016\/j.biopha.2023.114273","volume":"159","author":"N Zhao","year":"2023","unstructured":"Zhao, N. et al. Role of Interleukin-22 in ulcerative colitis. Biomed. Pharmacother. 159, 114273 (2023).","journal-title":"Biomed. Pharmacother"},{"key":"1939_CR17","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3389\/fimmu.2020.01315","volume":"11","author":"HX Wei","year":"2020","unstructured":"Wei, H. X., Wang, B. & Li, B. IL-10 and IL-22 in mucosal immunity: driving protection and pathology. Front. Immunol. 11, 1315 (2020).","journal-title":"Front. Immunol."},{"key":"1939_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/gutjnl-2019-318483","volume":"69","author":"N Powell","year":"2020","unstructured":"Powell, N. et al. Interleukin-22 orchestrates a pathological Endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. Gut 69, 578\u2013590 (2020).","journal-title":"Gut"},{"key":"1939_CR19","doi-asserted-by":"publisher","first-page":"G827","DOI":"10.1152\/ajpgi.00513.2005","volume":"290","author":"S Brand","year":"2006","unstructured":"Brand, S. et al. IL-22 is increased in active Crohn\u2019s disease and promotes Proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827\u2013838 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1939_CR20","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3748\/wjg.v19.i17.2638","volume":"19","author":"LZ Yu","year":"2013","unstructured":"Yu, L. Z. et al. Expression of interleukin-22\/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J. Gastroenterol. 19, 2638\u20132649 (2013).","journal-title":"World J. Gastroenterol."},{"key":"1939_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","volume":"153","author":"BE Sands","year":"2017","unstructured":"Sands, B. E. et al. Efficacy and safety of MEDI2070, an antibody against Interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study. Gastroenterology 153, 77\u201386e76 (2017).","journal-title":"Gastroenterology"},{"key":"1939_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ibd\/izab071","volume":"28","author":"LE Raffals","year":"2022","unstructured":"Raffals, L. E. et al. The development and initial findings of a study of a prospective adult research cohort with inflammatory bowel disease (SPARC IBD). Inflamm. Bowel Dis. 28, 192\u2013199 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"1939_CR23","doi-asserted-by":"crossref","unstructured":"Chen, T., Guestrin, C. & XGBoost: A Scalable Tree Boosting System. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. City; Association for Computing Machinery. 785\u2013794. (2016).","DOI":"10.1145\/2939672.2939785"},{"key":"1939_CR24","unstructured":"Curran Associates Inc., International Conference on Neural Information Processing Systems. A unified approach to interpreting model predictions. https:\/\/arxiv.org\/abs\/1705.07874. (Accessed 27 Sep 2023). (2017)."},{"key":"1939_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/gutjnl-2021-326451","volume":"72","author":"C Argmann","year":"2023","unstructured":"Argmann, C. et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut 72, 1271\u20131287 (2023).","journal-title":"Gut"},{"key":"1939_CR26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMra1814259","volume":"380","author":"A Rajkomar","year":"2019","unstructured":"Rajkomar, A., Dean, J. & Kohane, I. Machine learning in medicine. N. Engl. J. Med. 380, 1347\u20131358 (2019).","journal-title":"N Engl. J. Med."},{"key":"1939_CR27","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb, C. A. et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68, s1\u2013s106 (2019).","journal-title":"Gut"},{"key":"1939_CR28","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1074\/jbc.M207577200","volume":"278","author":"S Aggarwal","year":"2003","unstructured":"Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910\u20131914 (2003).","journal-title":"J. Biol. Chem."},{"key":"1939_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli, M. H. et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am. J. Gastroenterol. 110, 802\u2013819 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"1939_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.crohns.2011.05.003","volume":"5","author":"D Turner","year":"2011","unstructured":"Turner, D. et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J. Crohns Colitis. 5, 423\u2013429 (2011).","journal-title":"J. Crohns Colitis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:56:05Z","timestamp":1757400965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1939"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01939-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EK, JC, JN, MO, and CC: Employees and stock shareholders of AstraZeneca.\u00a0DFL, EAD, and UG: Former employees of AstraZeneca.\u00a0CS: Employee of the Kubrick Group, which was contracted by AstraZeneca to perform these analyses.\u00a0TF: Employee of the Crohn\u2019s & Colitis Foundation.\u00a0NP: Speaker, advisory consultant and\/or research grants from AbbVie, Allergan, AstraZeneca, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma UK Ltd, Ferring, Galapagos, Janssen, Roche, Pfizer, Sobi, Takeda, Tillotts, and Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This is a cross-sectional study of patients in the SPARC IBD cohort from the IBD Plexus registry of the Crohn\u2019s & Colitis Foundation. This study used patient data entered in SPARC IBD from initiation in 2016 to January 2022. The use of SPARC IBD and blood plasma samples for this study was approved by the Crohn\u2019s & Colitis Foundation in 2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients enrolled in the study provided informed consent to participate through a universal consent form authorizing use of their personal information for future IBD studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"30399"}}